What is retatrutide?

Retatrutide is one of the most talked-about names on the peptide frontier. The headline weight-loss figures from its trials are striking, and the interest is understandable. But the single most important fact about it is simple, and easy to lose in the excitement: it is not approved, and not available, anywhere in the world.

What it actually is

Retatrutide is an investigational, once-weekly triple hormone receptor agonist developed by Eli Lilly. Where semaglutide acts on one receptor (GLP-1) and tirzepatide on two (GLP-1 and GIP), retatrutide acts on three — GLP-1, GIP and glucagon. It is described as first-in-class for that triple-receptor approach.

This puts it firmly in the book's "frontier" territory: genuinely interesting science at the edge of the field, still working its way through the evidence process.

What the trial data shows

When Peptides: A Sober View went to press, retatrutide's Phase 2 data showed mean weight loss of around 24% at the highest dose over 48 weeks, with Phase 3 trials ongoing. Those Phase 3 results have since begun to arrive — and they have reinforced the picture rather than overturned it. Eli Lilly's TRIUMPH-1 obesity trial reported weight loss of up to around 28% of body weight at 80 weeks at the highest doses, figures that have drawn comparison to bariatric surgery, and a separate Phase 3 trial in type 2 diabetes also met its primary and key endpoints.

This is real, peer-process clinical data — a very different evidence base from the research-peptide compounds. But "impressive Phase 3 data" is not the same as "approved and available."

Why this matters right now

Because the data is impressive and the name is everywhere, retatrutide is exactly the kind of compound that attracts a grey market before it is ever approved. As of 2026 it remains investigational, with a regulatory filing not expected until 2027. Anything sold as "retatrutide" outside a clinical trial is, by definition, not the regulated product — and the book documents that counterfeit retatrutide-related products are already being marketed through unregulated channels, including a UK enforcement action against a vendor selling fake retatrutide and tirzepatide.

The sober bottom line

Retatrutide is a genuinely promising drug working through a genuine evidence process — and a name that is already being attached to unregulated products it has nothing to do with. Holding both of those facts at once is the whole point of the book's approach to the frontier.